SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.

doi:10.1080/14796694.2026.2651961

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.

Future oncology (London, England) - 1 Apr 2026

Peters Solange, Hochmair Maximilian, Arbour Kathryn C, Rodriguez Luis Paz-Ares, Reck Martin, Leal Ticiana, R Lindsay Colin, Shun Lu, William William Nassib, Spira Alexander I, Sabari Joshua K, Henning Grønberg Bjørn, Nishio Makoto, Burns Timothy F, Girard Nicolas, Capuzzo Frederico, Merced Alyson, Fasnacht Nicolas, Visseren-Grul Carla, Negrao Marcelo V

Abstract excerpt

CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov identifier is NCT06119581. EudraCT: 2023-503412-33-00. KRAS is a gene that everyone has that helps our cells grow in a controlled way. When this gene is mutated and active all the time, the cells in the body divide and can grow out of control. This can lead to several cancers, including lung cancer.This ongoing trial is assessing whether adding a new...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Carcinoma, Non-Small-Cell Lung

Share to Clinical Trials, Phase III as Topic

Share to KRAS gene

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 41940628
DOI: 10.1080/14796694.2026.2651961
PMCID: PMC13064562

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.PMID 41940628Read ↗

Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.Semantic proximity Read ↗

Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.Semantic proximity Read ↗

Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review.Semantic proximity Read ↗

KRAS-targeted therapy in the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.Semantic proximity Read ↗

KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians.Semantic proximity Read ↗

[Sotorasib treatment in KRAS G12C-mutated non-small cell lung cancer: Experience in the Tours university hospital].Semantic proximity Read ↗

A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC.Semantic proximity Read ↗

Treatment patterns and outcomes in KRASG12C-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.Semantic proximity Read ↗

An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.